| Literature DB >> 27888449 |
Abstract
Genus Salvia, commonly known as sage, is the largest genus in the Lamiaceae family. It comprises many species traditionally used as brain-enhancing tonics. In vitro and animal studies have confirmed that several Salvia species contain a large array of active compounds that may enhance cognitive activity and protect against neurodegenerative disease. In this review, the active constituents in plants belonging to the genus Salvia are summarised, and their influence on pharmacodynamics pertinent to cognitive activity are detailed. In particular, the effects of plants belonging to the genus Salvia and their constituents on cognitive skills including memory, attention and learning are detailed. Their potential effects in dementia, including Alzheimer's disease, are also examined. Completed human trials are summarised, and factors influencing the potency of Salvia plants are covered. Finally, directions for future research are proposed to enhance our understanding of the potential health benefits of Salvia plants.Entities:
Mesh:
Substances:
Year: 2017 PMID: 27888449 PMCID: PMC5318325 DOI: 10.1007/s40268-016-0157-5
Source DB: PubMed Journal: Drugs R D ISSN: 1174-5886
Common compounds identified in Salvia species
| Phenolic acids | Caffeic acid, rosmarinic acid, salvianolic acids, sagecoumarin, lithospermic acid, sagerinic acid, yunnaneic acids |
|---|---|
| Flavonoids | Luteolin, apigenin, hispidulin, kaempferol, quercetin |
| Terpenoids | α and β-Thujone, camphor, 1,8-cineole, α-humulene, β-caryophyllene, viridiflorol, carnosic acid, ursolic acid, carnosol, tanshinones |
| Polysaccharides | Arabinogalactans, pectin |
Fig. 1Major components in Salvia species and their pharmacodynamic effects in the brain
Summary of human trials investigating the cognitive effects of plants of Salvia species
| Study | Duration | Study design | Participants | Intervention | Main results |
|---|---|---|---|---|---|
| Alzheimer’s disease | |||||
| Akhondzadeh et al. [ | 4 months | Double-blind, placebo-controlled study | 30 patients completed trial with average age of 72 years |
| Over a 4-month period, people taking |
| Perry et al. [ | 6 weeks | Open-label design | 11 patients aged 76–95 years in whom a diagnosis of mild to moderate probable Alzheimer’s disease was established | Capsules contained 50 µL essential oil of | There were statistically significant reductions in neuropsychiatric symptoms and an improvement in attention from baseline to 6 weeks |
| Acute cognitive and mood effects | |||||
| Tildesley et al. [ | 6 h | Double-blind, placebo-controlled study | Trial 1, 20 healthy adults with a mean age of 20 years; Trial 2, 24 healthy adults with a mean age of 23 years | In Trial 1, 20 participants received 50, 100 and 150 µL of a standardised essential oil extract of | In Trial 1, memory performance was enhanced for the 50-µL dose at 1- and 2.5-hour time points. The effect was also apparent following administration of the 100 µL dose at 2.5 h post-dose sessions. A dose-specific enhancement on delayed word recall was also observed for the 50 µL dose at 1 and 2.5 h post-dose |
| Tildesley et al. [ | 6 h | Double-blind, placebo-controlled study | 24 healthy adults with a mean age of 23 years | Two identical capsules corresponding to a dose of either 0 (a sunflower oil placebo), 25 µL, or 50 µL of | Administration of |
| Kennedy et al. [ | 4 h | Double-blind, placebo-controlled study | 30 healthy adults with a mean age of 24 years | On each study day participants received 4 capsules of identical appearance, each containing either placebo or 150 mg of | Both doses of |
| Scholey et al. [ | 6 h | Double-blind, placebo-controlled study | 20 healthy, older-age adults with a mean age of 73 years | Each tablet contained either 167 or 333 mg of | Compared with the placebo condition, the 333-mg dose was associated with significant enhancement of secondary memory performance at all testing times. The same measure benefited to a lesser extent from other doses. There also were significant improvements to accuracy of attention following the 333-mg dose. In vitro analysis confirmed cholinesterase inhibiting properties for the extract |
| Moss et al. [ | Not specified | Randomised, single-blinded study | 135 healthy adults with a mean age of 22 years |
|
|
| Kennedy et al. [ | 4 h | Double-blind, placebo-controlled study | 36 healthy adults with a mean age of 24 years | A single soft gel capsule containing either 50 mL of | The essential oil was a potent inhibitor of human AChE and consisted almost exclusively of monoterpenoids. Oral consumption led to improved performance of secondary memory and attention tasks, most notably at the 1-hour post-dose testing session, and reduced mental fatigue and increased alertness, which were more pronounced 4-hours post-dose |
AChE acetylcholinesterase, DISS Daytime Insomnia Symptom Scale, GC gas chromatography, GC-MS gas chromatography-mass spectrometry
Safety of Saliva plant administration in chronic human trials
| Study | Study design | Population |
| Adverse events |
|---|---|---|---|---|
| Akhondzadeh et al. [ | 4-month, double-blind, placebo-controlled study | 30 patients with Alzheimer’s disease with an average age of 72 years | Ethanolic extract of | No difference in adverse events between |
| Perry et al. [ | 6-week, open-label design | 11 patients aged 76–95 years with probable Alzheimer’s disease | 50 µL essential oil of | Increased blood pressure in two patients with a history of hypertension |
| Bommer et al. [ | 8-week, open-label design | 69 women aged between 50 and 65 years (mean age 56 years), at least 12 months since last menstruation, at least five hot flushes daily | Once daily, 280-mg | 10 adverse events among 6 patients, of which 2 were related to study medication (mild abdominal pain and mild diarrhoea in one patient) |
| Vandecasteele et al. [ | 8-week, open-label design | 10 prostate cancer patients (median age 68) receiving androgen deprivation therapy and experiencing hot flashes | One 150-mg | Non-significant decrease in luteinising hormone and follicular stimulating hormone. One patient experienced acneiform skin eruption after 6 weeks on |
| Behradmanesh et al. [ | 12-week, double-blind, placebo-controlled study | 80 type II diabetic patients (average age 52 years) who had not reached the ideal control of the disease | One, 150-mg | 2 patients on active treatment reported mild gastrointestinal complaints, but did not require withdrawal from study |
| Kianbakht et al. [ | 8-week, double-blind, placebo-controlled study | 67 patients aged 20–60 years with newly diagnosed primary hyperlipidaemia | One, 500-mg ethanolic/aqueous extract of | No reported adverse events |
|
|
| Several studies have confirmed the many |
| Further research is required to examine the longer-term cognitive-enhancing effects of |